NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive. For more information, submit a form at Sarepta Therapeutics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb. ...

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the “Class Period”), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit. Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta and certain of Sarepta’s t ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period from June 22, 2023, to June 24, 2025, due to alleged misleading statements regarding the safety and efficacy of their gene therapy product, ELEVIDYS [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Sarepta Therapeutics made false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks and failed to detect severe side effects [5]. - The lawsuit alleges that the adverse events from ELEVIDYS treatment would lead to a halt in recruitment and dosing in trials, attract regulatory scrutiny, and increase risks around the therapy's approvals [5]. - Investors are encouraged to join the class action without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. due to allegations of misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to severe adverse events including patient deaths [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [2]. - The class period for the lawsuit is defined as between June 22, 2023, and June 24, 2025, during which investors acquired Sarepta securities [1]. Group 2: Impact of Adverse Events on Stock Price - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [3]. - Following the announcement on April 4, 2025, regarding regulatory scrutiny and the halting of recruitment in some clinical studies, Sarepta's stock fell more than 7% [4]. - A second patient death was reported on June 15, 2025, leading to a suspension of ELEVIDYS shipments and a further stock decline of over 42% [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure cases, causing an additional stock drop of more than 8% [6]. Group 3: Investor Actions - Investors who purchased Sarepta shares are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline of August 25, 2025, to discuss their rights and interests in the class action [7].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, for Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects in trials, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - Investors who purchased Sarepta securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to the safety of its product ELEVIDYS, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by August 25, 2025 [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Sarepta and its executives made false or misleading statements regarding the safety of ELEVIDYS, failing to disclose significant safety risks and adverse events associated with the treatment [5]. - The firm encourages investors who suffered losses exceeding $100,000 in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1][3]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [6]. - On April 4, 2025, after disclosing that EU authorities requested a review of the death, the stock price dropped by $4.18 per share, or 7.13%, closing at $54.43 [8]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24 per share, or 42.12%, closing at $20.91 [10]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [11].

Core Viewpoint - Sarepta Therapeutics is facing a class action lawsuit due to alleged misleading statements and undisclosed safety risks related to its gene therapy product ELEVIDYS, which has resulted in significant stock price declines following patient deaths and regulatory scrutiny [3][4][5][6][7]. Group 1: Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for Duchenne muscular dystrophy, including the gene therapy product ELEVIDYS [3]. Group 2: Allegations and Legal Actions - The class action lawsuit claims that Sarepta made false or misleading statements regarding ELEVIDYS, including significant safety risks and inadequate clinical trial protocols [3]. - The lawsuit highlights that adverse events related to ELEVIDYS forced Sarepta to pause recruitment and dosing in trials, which jeopardized regulatory approvals [3]. Group 3: Stock Price Impact - Following the disclosure of a patient death from acute liver failure on March 18, 2025, Sarepta's stock dropped more than 27% [4]. - An additional announcement on April 4, 2025, regarding a review by European regulatory authorities led to a further 7% decline in stock price [5]. - A second patient death reported on June 15, 2025, caused the stock price to decline over 42% [6]. - The FDA's Safety Communication on June 24, 2025, regarding the investigation of patient deaths resulted in an additional 8% drop in Sarepta's stock [7].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, alleging securities fraud related to the company's gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy. The lawsuit claims that Sarepta made false statements about the safety and revenue outlook of ELEVIDYS, misleading investors about its potential for broader application approval and growth in prescriptions [1][4][5]. Group 1: Allegations and Impact - The complaint alleges that Sarepta misled investors by claiming that ELEVIDYS was a safe therapy without significant risks, while failing to disclose serious safety concerns and adverse events associated with the treatment [4][5]. - Specific allegations include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and that adverse events would lead to halted recruitment and increased regulatory scrutiny [5]. - Following the announcement of a patient death related to ELEVIDYS on March 18, 2025, Sarepta's stock price dropped by $27.81 per share, or 27.44%, closing at $73.54 [6]. Group 2: Subsequent Developments - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a halt in recruitment for some clinical studies, which caused the stock price to fall by $4.18 per share, or 7.13%, to close at $54.43 [7]. - A second patient death was reported on June 15, 2025, resulting in a significant stock price drop of $15.24 per share, or 42.12%, closing at $20.91 [8]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks associated with ELEVIDYS, leading to a further decline in stock price by $1.52 per share, or 8.01%, closing at $17.46 [9].

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Why is Sarepta being Investigated? Sarepta is a biopharmaceutical company focused on developing treatment ...

Core Viewpoint - The FDA is investigating the risk of acute liver failure associated with Sarepta Therapeutics' Elevidys treatment, which has resulted in serious outcomes including hospitalization and death [1][2]. Group 1: FDA Investigation - The FDA has received two reports of fatal acute liver failure in non-ambulatory pediatric male patients with Duchenne Muscular Dystrophy (DMD) following treatment with Elevidys [2]. - The agency is evaluating the need for further regulatory action based on these reports [1]. Group 2: Patient Outcomes - In the reported cases, patients exhibited elevated transaminases and were hospitalized within two months after receiving Elevidys [3]. - Both fatalities appear to be directly related to the treatment with Elevidys [2]. Group 3: Analyst Reactions - HC Wainwright has reiterated a Sell rating for Sarepta, maintaining a price forecast of $10, citing the likelihood of the FDA requiring updated warnings regarding liver failure or death [4]. - The worst-case scenario for Sarepta would involve the FDA mandating the withdrawal of Elevidys from the U.S. market [4][5]. Group 4: Company Valuation - If Elevidys were to be withdrawn, analysts believe there would be little intrinsic value remaining in Sarepta [5]. - The skepticism from FDA officials regarding the initial approval of Elevidys suggests potential challenges for the company's continued marketing efforts [6]. Group 5: Stock Performance - Following the news, Sarepta's stock (SRPT) has seen a decline of approximately 9.96%, trading at $17.09 [6].